Some Investors May Be Willing To Look Past Revvity's (NYSE:RVTY) Soft Earnings
Revvity, Inc. (NYSE:RVTY) Is a Favorite Amongst Institutional Investors Who Own 81%
Life Science Tools and Reagents Market Report 2024, With Profiles of BD, Bio-Rad Laboratories, Danaher, F. Hoffmann-La Roche, Merck, Promega, Qiagen, Revvity, Takara Bio and Thermo Fisher Scientific
Decoding Revvity Inc (RVTY): A Strategic SWOT Insight
Revvity | 10-Q: Q2 2024 Earnings Report
While the S&P 500 Sinks, Kellanova Stock Is Rising. Here's Why. -- Barrons.com
S&P 500 Futures Decline In Premarket Trading; First Fincl Bankshares, MicroStrategy Lag
Analysts Have Conflicting Sentiments on These Healthcare Companies: Revvity (RVTY), PTC Therapeutics (PTCT) and Tectonic Therapeutic (TECX)
Baird Adjusts Price Target on Revvity to $136 From $127
A Quick Look at Today's Ratings for Revvity(RVTY.US), With a Forecast Between $125 to $145
Revvity Price Target Raised to $125.00/Share From $115.00 by Barclays
Express News | Revvity : Barclays Raises Target Price to $125 From $115
Express News | Revvity Inc : Raymond James Raises Target Price to $144 From $127
Revvity Is Maintained at Neutral by B of A Securities
Express News | B of A Securities Maintains Neutral on Revvity, Raises Price Target to $127
Express News | Revvity Inc : Stifel Raises Target Price to $120.00 From $110.00
Express News | Revvity Inc : BofA Global Research Raises Price Objective to $127 From $118
Revvity's Balanced Performance Amidst Market Challenges: A Hold Recommendation With Updated Price Objective
Barclays Sticks to Their Hold Rating for Revvity (RVTY)
Express News | Revvity Inc : Evercore ISI Raises Target Price to $132 From $126